Document

0000875320-16-000085.txt : 20170320 0000875320-16-000085.hdr.sgml : 20170320 20160711095058 ACCESSION NUMBER: 0000875320-16-000085 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20160711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 CORRESP 1 filename1.htm Document

VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE • BOSTON, MA 02210-1862

TEL. 617-341-6100 • http://www.vrtx.com

July 11, 2016

Delivered via EDGAR

Securities and Exchange Commission
Division of Corporation Finance

100 First Street, N.E.

Mail Stop 4720

Washington, DC 20549

Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant

Re: Vertex Pharmaceuticals Incorporated

Form 10-K for the Fiscal Year Ended December 31, 2015

Filed February 16, 2016

File No. 000-19319

Ladies and Gentlemen:

The purpose of this letter is to confirm receipt of comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) to Vertex Pharmaceuticals Incorporated (the “Company”) set forth in the Staff’s letter to Jeffrey M. Leiden, dated June 30, 2016 (the “Comment Letter”), regarding the Company’s Form 10-K for the fiscal year ended December 31, 2015.

Based on the Company’s conversation with Ms. Bonnie Baynes, Staff Accountant for the Commission, with your permission the Company hereby agrees to submit its response to the Comment Letter no later than August 12, 2016. The Company plans to use this extra time to more thoroughly address the Staff’s comments.

Please contact me at (617) 961-7018 if you have any questions or concerns with respect to this matter.

Very truly yours,

/s/ Michael J. LaCascia

Michael J. LaCascia

Senior Vice President and General Counsel

GRAPHIC 2 secextensionletterimage1.jpg begin 644 secextensionletterimage1.jpg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end